Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ANAPTYSBIO, INC

Get SEC filing alerts via email and in your feed for ANAPTYSBIO, INC

ANAB

ANAPTYSBIO, INC

About ANAPTYSBIO, INC

AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead product, rosnilimab, targets PD-1+ T cells and is in Phase 2b trials for rheumatoid arthritis and ulcerative colitis. With a focus on underserved patient populations, AnaptysBio aims to leverage its antibody pipeline and collaborations, including with GlaxoSmithKline, to address significant market opportunities in immunology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ANAPTYSBIO, INC

1
1
ANAPTYSBIO, INC AnaptysBio Reports Q1 2026 Financial Results, Net Loss Increases to $52.9 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
ANAPTYSBIO, INC AnaptysBio Reports $234.6M Collaboration Revenue and Plans Company Separation

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ANAPTYSBIO, INC AnaptysBio Reports $76.3M Collaboration Revenue and Plans Strategic Separation

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ANAPTYSBIO, INC AnaptysBio Reports Increased Collaboration Revenue of $22.3 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ANAPTYSBIO, INC AnaptysBio Reports Significant Revenue Growth and Strategic Developments in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ANAPTYSBIO, INC AnaptysBio Reports $91.3 Million Collaboration Revenue and Narrows Net Loss in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
ANAPTYSBIO, INC AnaptysBio Reports Significant Financial Growth, Collaboration Revenue Increase in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments